- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02359006
The Effects of Minocycline in Opioid-maintained Patients
The Effects of Minocycline on Opioid-induced Hyperalgesia in Opioid-Maintained Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sixty completers will be recruited through the VA methadone clinic, as well as through the APT Foundation Methadone Maintenance Program. After the initial phone screening, potential subjects will undergo a comprehensive evaluation which will include medical, psychiatric, and drug use histories as well as physical, psychiatric, and laboratory examinations. Laboratory examination will include CBC, liver and thyroid function tests, serum electrolytes, BUN, creatinine, PT, PTT, urine analysis (including urine pregnancy for women) and urine toxicology screening.
Participants will be terminated from the study following opioid relapse, or use of any other psychotropic medications. If participants are noncompliant (no-show, positive urine screening, noncompliance with medication protocol/missing more than one dose of minocycline/placebo), participation will be terminated.
This double-blind, randomized clinical trial will randomize male and female veterans and non-veterans currently undergoing methadone maintenance treatment for opioid dependence to either minocycline (200mg/day) or placebo for 15 days. Upon inclusion, participants will be subjected to a pain assessment to evaluate baseline pain thresholds and tolerance: the Cold Pressor Test. An experimental treatment of either minocycline or placebo will then be initiated and maintained for 15 days. Additionally, at the beginning of Week 2 of treatment, participants will be given a Personal Digital Assistant (PDA) an HP iPAQ Pocket PC 2003 Pro that will administer Ecological Momentary Assessments (EMA). Using EMA, we can assess change in pain sensitivity, withdrawal symptoms and cognitive performance in the participants' natural environment, which increases the ecological validity of the study. Participants will be asked to return to the laboratory several times a week for the 15 consecutive days that they are taking minocycline in order to receive the study medication and to assess changes in pain thresholds and tolerance (i.e. to assess the presence, or lack thereof of hyperalgesia). Upon completion of experimental treatment, participants will be asked to return a final time to undergo pain measurement once more, to assess any changes in pain sensitivity after completion of minocycline.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Connecticut
-
West Haven, Connecticut, United States, 06516
- VA Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females, between the ages of 18 and 55
- Diagnosed with opioid dependence and currently enrolled in methadone maintenance treatment
- Compliant in methadone maintenance treatment and on a stable dose for two weeks or greater
- No current dependence or abuse of any other drugs (other than tobacco or marijuana)
- No current medical problems
For women:
- not pregnant as determined by pregnancy screening;
- not breast feeding; u
- using acceptable birth control methods;
- not experiencing moderate to severe premenstrual symptoms (may interfere with pain assessment);
- regular menstrual cycles
Exclusion Criteria:
- Current major psychiatric illnesses including mood, psychotic, or anxiety disorders
- History of major medical illnesses, including liver diseases, heart disease, or other medical conditions that the physician investigator deems contraindicated for inclusion in the study
- Current use of over-the-counter or prescription psychoactive drugs (including regular use of NSAIDS, antidepressant, anxiolytics, antipsychotics, mood stabilizers, psychostimulants) or drugs that would be expected to have major interactions with drugs to be tested, e.g., benzodiazepines, codeine, Percocet, and other opiate drugs
- Liver function tests (ALT or AST) greater than 3x normal
- Allergy to minocycline or other tetracyclines
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: minocycline
200mg minocycline
|
Minocycline will be compared with placebo
Other Names:
|
Placebo Comparator: Placebo
Sugar pill
|
Placebo will be compared with minocycline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Threshold
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
The Cold Pressor Test (CPT) measures pain threshold (in seconds).
For this test, two water coolers filled with either warm (100.04ºF/37.8ºC)
or cold water (32.9-34.7ºF/0.5-1.5ºC) are used.
To begin the CPT, participants first immerse their hand into the warm-water bath for 2 min.
Participants are then instructed to immerse their hand into the cold water bath and report the first time they experience pain (pain threshold).
Lower scores indicate lower pain threshold.
Minimum score is 0 seconds, and a maximum cut-off score of 300 seconds is used to prevent tissue damage.
|
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Pain Tolerance
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
The Cold Pressor Test (CPT) measures pain threshold and pain tolerance (in seconds).
For this test, two water coolers filled with either warm (100.04ºF/37.8ºC)
or cold water (32.9-34.7ºF/0.5-1.5ºC) are used.
To begin the CPT, participants first immerse their hand into the warm-water bath for 2 min.
Participants are then instructed to immerse their hand into the cold water bath and report when the pain becomes unbearable (pain tolerance).
Lower scores indicate lower pain tolerance.
Minimum score is 0 seconds, and a maximum cut-off score of 300 seconds is used to prevent tissue damage.
|
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brief Pain Inventory - Short Form: Pain Severity
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Brief Pain Inventory - Short Form: BPI-SF is a self-report questionnaire that assesses the impact of pain on daily function, location of pain, pain medications, and amount of pain relief in the past 24 hours or the past week.
Each question is scored 0-10, and the scores are summed and then averaged to create a pain severity score.
Minimum score is 0; maximum score is 10.
Higher scores indicate more severely perceived pain.
|
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Brief Pain Inventory - Short Form: Interference
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Brief Pain Inventory - Short Form: BPI-SF is a self-report questionnaire that assesses 7 questions each rated on a scale of 0-10, which are added and divided by 7. This average score of 7 questions gives a "pain interference with living" score, with a minimum score of 0 and a maximum score of 10. Higher scores indicate that pain interferes more with aspects of daily life. |
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Opioid Withdrawal Symptom Checklist (OWSC): Back Pain Item
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
For safety reasons, withdrawal signs and symptoms were assessed using a 22-item withdrawal instrument that has been reliably used to assess opiate withdrawal.
As an additional assessment of daily pain, the presence of "back pain" item was analyzed.
This item has a minimum score of 0 and maximum score of 4, with higher scores indicates more agreement with statement/more back pain.
|
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Profile of Mood States (POMS) Depression Subscale
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
The POMS is a 65-item scale that divides items amongst eight mood states (tension, depression, anger, fatigue, confusion, vigor) on a 5-point rating scale (0=not at all to 5=extremely).
We analyzed the 15-item "Depression" subscale, which has a minimum score of 0 and a maximum score of 75.
Higher score indicate more agreement with the statement/more feelings of depression.
|
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Profile of Mood States (POMS) - Total Mood Disturbance
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
The POMS is a 65-item scale that divides items amongst eight mood states (tension, depression, anger, fatigue, confusion, vigor) on a 5-point rating scale (0=not at all to 5=extremely).
Total Mood Disturbance is calculated by adding the "tension, depression, anger, fatigue, and confusion" subscale scores and subtracting the "vigor" subscale score.
This has a minimum of 0 and a maximum score of 210.
Higher score indicate more mood disturbance.
|
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Short-Form McGill Pain Questionnaire (SF-MPQ): Sensory Subscale
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
This measure is a subscale of the SF-MPQ, comprised of 11 of the 15 total items.
The measure is completed immediately after the CPT, where participants describe their experience of CPT pain by choosing among a series of possible answers [none (score=0), mild (score=1), moderate (score=2), or severe (score=3)].
The items to describe the pain are 'Throbbing','Shooting', 'Stabbing', 'Sharp', 'Cramping', 'Gnawing', 'Hot/burning', 'Aching', 'Heavy', 'Tender', and 'Splitting'.
The scores for these 11 items are summed as a measure of Sensory pain, with a minimum score of 0 and a maximum score of 33.
|
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Short-Form McGill Pain Questionnaire (SF-MPQ): Affective Subscale
Time Frame: One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
This measure is a subscale of the SF-MPQ, comprised of 4 of the 15 total items.
The measure is completed immediately after the CPT, where participants describe their experience of CPT pain by choosing among a series of possible answers [none (score=0), mild (score=1), moderate (score=2), or severe (score=3)].
The items to describe the pain are 'Tiring-Exhausting', 'Sickening', 'Fearful', 'Punishing-Cruel'.
The scores for these 4 items are summed as a measure of Affective pain, with a minimum score of 0 and a maximum score of 12.
|
One measurement at each of 5 weekly sessions: Baseline, Day 8, Day 15, Day 22 and at Follow-up (~Day 28)
|
Interleukin-1 Beta (IL-1β)
Time Frame: Pre/post : At Screening before medication, and on Day 22 of medication
|
Serum cytokine analysis assayed using electrochemiluminescence multi-array technology (Meso Scale Discovery, Gaithersburg, MD).
IL-1β is measured in pictograms per milliliter (pg/ml).
Cytokines were assessed at screening (approximately 1 week prior to medication), and on the last day of medication treatment.
Higher numbers indicate higher blood levels of this cytokine.
|
Pre/post : At Screening before medication, and on Day 22 of medication
|
Interleukin-6 (IL-6)
Time Frame: Pre/post : At Screening before medication, and on Day 22 of medication
|
Serum cytokine analysis assayed using electrochemiluminescence multi-array technology (Meso Scale Discovery, Gaithersburg, MD).
IL-6 is measured in pictograms per milliliter (pg/ml).Cytokines were assessed at screening (approximately 1 week prior to medication), and on the last day of medication treatment.
Higher numbers indicate higher blood levels of this cytokine.
|
Pre/post : At Screening before medication, and on Day 22 of medication
|
Tumor Necrosis Factor Alpha (TNF-α)
Time Frame: Pre/post : At Screening before medication, and on Day 22 of medication
|
Serum cytokine analysis assayed using electrochemiluminescence multi-array technology (Meso Scale Discovery, Gaithersburg, MD).
TNF-α is measured in pictograms per milliliter (pg/ml).Cytokines were assessed at screening (approximately 1 week prior to medication), and on the last day of medication treatment.
Higher numbers indicate higher blood levels of this cytokine.
|
Pre/post : At Screening before medication, and on Day 22 of medication
|
Ecological Momentary Assessments (EMA) - Pain
Time Frame: 4x/day for one week
|
Participants will be asked "Do you feel any pain at this moment" on seven-point Likert scales (1=strongly disagree to 7=strongly agree) 4 times per day outside of the laboratory (in their natural environment) using a personal digital assistant on days 8-14 of medication treatment.
All scores were averaged to compute one score.
Higher scores indicate more feelings of pain.
|
4x/day for one week
|
Ecological Momentary Assessments (EMA) - Craving
Time Frame: 4x/day for one week
|
Participants will be asked "Are you craving heroin at this moment" on seven-point Likert scales (1=strongly disagree to 7=strongly agree) 4 times per day outside of the laboratory (in their natural environment) using a personal digital assistant on days 8-14 of medication treatment.
All scores were averaged to compute one score.
Higher scores indicate more craving for heroin.
|
4x/day for one week
|
Ecological Momentary Assessments (EMA): SOWS
Time Frame: 4x/day over one week
|
Self-report opioid withdrawal scale.
Withdrawal symptoms are measured on a 7-point Likert scale (1=strongly disagree, 7=strongly agree).
Participants complete these ratings 4 times per day on days 8-14 of medication treatment.
All scores were averaged to compute one score.
Higher scores indicate more withdrawal symptoms.
|
4x/day over one week
|
Digit Symbol Substitution Test
Time Frame: Baseline (Day 0), Pre- and 1-hour post-medication treatment on Test Days 8, 15 and 22, and at Follow-up (~Day 28
|
The DSST is a test of psychomotor performance, which measures motor persistence, sustained attention, response speed and visuomotor coordination.
The task is to fill in blank spaces with the symbols that are paired with the number above the blank space as fast as possible for 90 sec.
The minimum score is 0 and the maximum score is 120.
Higher numbers indicate better cognitive performance.
|
Baseline (Day 0), Pre- and 1-hour post-medication treatment on Test Days 8, 15 and 22, and at Follow-up (~Day 28
|
Sustained Attention to Response Test (SART): No-go Trials: Errors of Commission
Time Frame: Baseline (Day 0), Pre- and 1-hour post-medication treatment on Test Days 8, 15 and 22, and at Follow-up (~Day 28
|
The SART is a Go No-Go task.
It assesses the ability to withhold responses to an infrequently occurring target (No-Go trials).
A total of 225 single digits (25 x 9 digits) are presented on a computer monitor for 250 ms each, immediately followed by a mask for 900 ms.
Subjects must press a spacebar in response to every digit except the "3".
Higher numbers indicate more errors of commission.
|
Baseline (Day 0), Pre- and 1-hour post-medication treatment on Test Days 8, 15 and 22, and at Follow-up (~Day 28
|
Sustained Attention to Response Test (SART): Go Trials: Errors of Omission
Time Frame: Baseline (Day 0), Pre- and 1-hour post-medication treatment on Test Days 8, 15 and 22, and at Follow-up (~Day 28
|
The SART is a Go No-Go task.
It assesses the ability to withhold responses to an infrequently occurring target (No-Go trials).The SART is a Go No-Go task.
It assesses the ability to withhold responses to an infrequently occurring target (No-Go trials).
A total of 225 single digits (25 x 9 digits) are presented on a computer monitor for 250 ms each, immediately followed by a mask for 900 ms.
Subjects must press a spacebar in response to every digit except the "3".
Higher numbers indicate more errors of omission.
|
Baseline (Day 0), Pre- and 1-hour post-medication treatment on Test Days 8, 15 and 22, and at Follow-up (~Day 28
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D., Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1412015119
- 2T32DA007238-26 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Minocycline
-
Journey Medical CorporationDr. Reddy's Laboratories LimitedCompleted
-
State University of New York - Downstate Medical...RecruitingAsthma | Allergic RhinitisUnited States
-
Central South UniversityCompleted
-
OraPharmaCompleted
-
Rempex (a wholly owned subsidiary of Melinta Therapeutics...Innovative Medicines Initiative; Universitätsklinikum KölnTerminatedRenal Insufficiency, Chronic | Healthy Subjects | Renal Insufficiency, AcuteGermany
-
Johns Hopkins UniversityMakerere UniversityTerminatedHIV Infections | HIV-associated Cognitive ImpairmentUganda
-
University of PittsburghTerminated
-
Ain Shams Universityfaculty of pharmacy Tanta UniversityNot yet recruiting
-
University of South FloridaCompleted
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.RecruitingIschemic Stroke, AcuteChina